Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.35
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€219.70M
Enterprise Value€305.98M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)49.8
Beta0.34
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.11
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Pharma + CDMO Business ModelA dual revenue model—branded/specialty pharmaceuticals plus CDMO services—provides durable revenue diversification. Long-term, contract manufacturing can smooth utilization and margins, while product sales preserve market exposure, reducing reliance on any single product or client.
Historical Revenue Expansion (2020–2024)Multi-year top-line expansion through 2024 evidences prior successful market penetration and commercial execution. That track record indicates the company can grow share and scale operations, supporting potential recovery if operational headwinds behind the 2025 decline are addressed.
Moderate Leverage And Growing Equity BaseHistorically moderate leverage and gradual equity growth provide financial flexibility and resilience versus highly leveraged peers. A stronger equity base supports borrowing capacity for capex or contract wins and cushions cycles, making the balance sheet structurally more robust over time.
Bears Say
Sharp 2025 Revenue Decline & Margin HitA sudden, large revenue drop combined with near-break-even margins is structurally damaging: it erodes pricing power, reduces reinvestment capacity for R&D and commercial effort, and can trigger longer-term market-share losses if recovery is slow or competitors capitalize on weakness.
Weak Cash Generation; Negative Free Cash FlowSharp deterioration to negative free cash flow undermines self-funding of operations and capital projects. Persistent or repeated FCF deficits increase reliance on external financing, raise refinancing risk, and constrain the company’s ability to invest in capacity or win new long-term CDMO contracts.
Rising Leverage In The Weakest YearLeverage rising into 2025 amid collapsing profitability elevates solvency and interest-service risk. Higher debt loads limit strategic flexibility, increase fixed costs, and can force defensive capital allocation choices that impair long-term growth or delay needed reinvestment.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.35 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €219.70M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is in 30 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on May 07, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.087%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Options Prices
Currently, No data available
---